Çiçekli Esen, Sayan Saadet, Kotan Dilcan
Department of Neurology, Akyazı State Hospital, Sakarya, Turkey.
Department of Neurology, Sakarya University Training and Research Hospital, Turkey.
Mult Scler Relat Disord. 2022 Apr;60:103674. doi: 10.1016/j.msard.2022.103674. Epub 2022 Feb 6.
BACKGROUND/AIM: Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease. Fibrinogen/Albumin ratio (FAR) has been studied as an inflammatory marker in the past, and its significant relationship with inflammation has been shown. In our study, we examined serum levels of albumin, fibrinogen and FAR in patients presenting with MS attack. We investigated its usability in the diagnosis and management of MS attacks.
This retrospective study included 40 patients admitted to hospital with MS attack and 40 control patients. All patients' demographics, medical history, the mean Expanded Disability Status Scale (EDSS), imaging findings and laboratory tests were extracted from medical records. Patients' fibrinogen, albumin levels were recorded in the blood tests performed before steroid administration, and FAR values were calculated. The patients' and controls' results were compared.
Fibrinogen and FAR values were significantly higher in the patient group (p<0.001 in both). There was no difference between the patient and control groups in terms of albumin (p = 0,16). No significant relationship was found between parameters such as EDSS, disease duration, smoking status and FAR value (p>0.05 in all).
Serum fibrinogen and FAR levels in the patients presenting with an attack were significantly higher than the control group. FAR value did not vary with disease duration and EDSS score. Based on this information, FAR may be a useful indicator for MS attack regardless of EDSS and disease duration.
背景/目的：多发性硬化症（MS）是一种慢性中枢神经系统炎症性疾病。纤维蛋白原/白蛋白比值（FAR）过去已作为一种炎症标志物进行研究，并且已显示出其与炎症的显著关系。在我们的研究中，我们检测了多发性硬化症发作患者的血清白蛋白、纤维蛋白原水平及FAR。我们研究了其在多发性硬化症发作诊断和管理中的可用性。
这项回顾性研究纳入了40例因多发性硬化症发作入院的患者和40例对照患者。从病历中提取了所有患者的人口统计学资料、病史、平均扩展残疾状态量表（EDSS）、影像学检查结果和实验室检查结果。记录患者在使用类固醇之前进行的血液检查中的纤维蛋白原、白蛋白水平，并计算FAR值。比较患者和对照组的结果。
患者组的纤维蛋白原和FAR值显著更高（两者均p<0.001）。患者组和对照组在白蛋白方面无差异（p = 0.16）。在EDSS、病程、吸烟状况等参数与FAR值之间未发现显著关系（所有p>0.05）。
发作患者的血清纤维蛋白原和FAR水平显著高于对照组。FAR值不随病程和EDSS评分而变化。基于此信息，无论EDSS和病程如何，FAR可能是多发性硬化症发作的一个有用指标。
